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1INTRODUCTION
Gastroesophageal junction tumors  are considered to be those tumors
whose epicenter lies   within the  5 cm range(totally-10cm) on either side
of  anatomic gastro-esophageal junction. A cancer  in the stomach with its
epicenter  5cm  beyond  the gastroesophageal junction aborally, and also
those  within 5 cm  but not encroaching  the gastroesophageal junction, are
considered  as proximal gastric cancer.  Endoscopically the gastro
esophageal junction is defined as the place where distal end of esophageal
longitudinal vessels meet the proximal ends of gastric mucosal folds.
Histological confirmation of the esophagus  is needed by identifying the
distal end of esophageal squamous mucosa, its multilayered epithelium
and the deep esophageal sub mucosal glands or ducts .  Identification of
the proximal end of  gastric oxyntic mucosa is also useful. In hiatus hernia
the squamocolumnar junction is not a reliable marker of gastro esophageal
junction. The most common tumors to arise in this area is the
adenocarcinoma and the squamous cell carcinoma. This is a heterogeneous
group comprising both , esophageal and gastric carcinoma and the true
junctional type tumors.
2There is a dramatic rise  in  the incidence of gastroesophageal
junctional adenocarcinoma (GEJ)  while its  prognosis still remains poor .
The possibility of  offering a cure is 50% only as they present  late.
•  Siewert et al  proposed  a  classification  of  adenocarcinomas
which arise near the  gastro-esophageal junction   in 1996. This was
accepted by the second international congress on carcinoma stomach
.This was slightly modified later in 2000. The clinicopathological
characteristics of each group differ and this classification help in
planning treatment accordingly.
Type I
The tumor epicenter lies within  1–5 cm proximal to the gastro-
oesophageal junction. These tumors behave like distal   esophageal
adenocarcinomas.
3Type II
Tumor epicenter  lies within 1cm above and 2cm below the gastro-
oesophageal junction . Intestinal metaplasia is seen in only 10% of type II
tumors. The biological behavior  thus parallels the adenocarcinoma of the
cardia of stomach rather than  esophagus.
Type III
Subcardial tumor  whose epicenter lies within 2-5cm distal to the
gastro esophageal junction and involves the gastroesophageal junction.
Proximal gastric cancer not involving the  gastroesophageal junction
are not included in this type even though these tumors behave like gastric
adenocarcinomas.
4AIM OF THE STUDY
To study   the epidemiology, clinical presentation, age group
affected, sex ratio, resectability, type of surgical procedure, margin status,
pathological type of tumors ,complications occurring post surgery
including death  in the patients presenting to  our department ( Surgical
Gastroenterology and proctology) during the study period from
August2010 to February 2013
Inclusion criteria
All patients with gastroesophageal junction tumors   who have
resectable disease by imaging  and in whom surgery is planned .
Exclusion criteria
Patients with carcinoma lower third of  esophagus  not encroaching
the  anatomic gastro esophageal junction  ,Carcinoma esophagus  with
epicenter beyond 5cm  on the oral side of the anatomic gastroesophageal
junction.  Carcinoma  arising in the cardia of stomach but not involving
gastroesophageal junction and those with epicenter 5cm beyond GEJ
aborally.Carcinoma of  GEJ with distant metastasis identified
preoperatively.
5REVIEW OF LITERATURE
Adenocarcinomas of the gastroesophageal junction (GEJ) were
uncommon in the early 20th century, overshadowed by the far more
common distal gastric and proximal squamous esophageal cancers. Over
the past 3decades  this relationship has reversed with the incidences of
proximal esophageal cancer and distal gastric cancers have declining
significantly, while  the incidences of distal esophageal and proximal
gastric cancers i.e cancer around the gastroesophageal junction is
increasing. The above trend  is particularly marked in  the Western
population. Genetic, ethnic, and cultural differences between populations
appear to be contributing to the burden of disease in the west. The
incidence  of adenocarcinoma of oesophageal in Asian people is very low ,
even in those who live in the United States, while these people have
higher incidence of gastric cardia adenocarcinoma .
Adenocarcinomas mainly arise in the distal third esophagus and
gastroesophageal junction .They  arise from glandular epithelium  with a
papillar or tubular structure. This may be  from Barrett metaplasia or from
glandular metaplasia in the esophageal mucosa. Mortality associated with
GE junction tumors has remained high, in spite of the technological
advancement and advances in the critical care management. After surgical
resection alone  the  5-year survival rate  is  less than 30%.
6Risk Factors and Etiology:
• For squamous cell carcinoma  arising in the region of
gastroesophageal junction there is no doubt about the cell of origin
.Alcohol and tobacco consumption are the major risk factors for
squamous cell carcinoma . Almost all the patients with  squamous
cell carcinoma except 5%  have a history of  smoking.The risk
increases with increasing pack years.
• Cyclo oxygenase 2 is an important  enzyme  in the development of
gastrointestinal cancers and this holds true in  esophageal
carcinomas also. Cox 2 acts by increasing cell life  by stimulating
angiogenesis and inhibiting apoptosis. So intermittent and frequent
use of  NSAIDS and asprin which are inhibitors of cyclooxygenase
were shown to be protective against gastrointestinal tumors
• Diet and nutrition: Decreased intake of vitamin c and E is
significantly associated with development of both squamous and
adenocarcinoma and high fruit and vegetable intake decrease the
risk for both types. Supplementation  of  the above  has shown to
decrease death rate.
• Whether a viral agent is implicated  as one of the factors for mitotic
transformation has yet to be elucidated.
7Esophagel adenocarcinoma specific risk factors:
Barrett’s esophagus:
Barrett’s esophagus is the most important risk factor for esophageal
adenocarcinoma. In studies with a large sample size, the risk for
development of esophageal adenocarcinoma was 30- to 60-fold higher in
patients with Barrett esophagus than in the general population. Most
adenocarcinomas (from 20% to 80%) seem to arise from specialized
columnar metaplastic epithelium .The  mitotic risk  increases by about 1%
per year more so with intestinal metaplasia
GERD: 30 % of the people in the west are affected by GERD. There
have been many epidemiological studies showing  a positive association
between  GERD and  esophageal adenocarcinomas. In a national wide
Swedish study the odds ratio for  having adenocarcinoma of esophagus in
people with  long standing and severe reflux  was 43.5.
Obesity/ High BMI:
Kubo et al performed a systematic review and meta-analysis about
the association of BMI and the risk of esophageal adenocarcinoma. They
demonstrated that  when the body mass index  was  more than 25,there
8was an increased risk for adenocarcinoma  of esophagus  in both men and
women and higher levels of BMI were associated with increased risk.
• Tobacco and alcohol consumption also causes Adenocarcinoma
but very less when compared to a  squamous cell carcinoma.
Smoking is moderate risk factor  for adenocarcinoma while
alcohol does not seem to have an increased association.
• Dysplasia in the squamous epithelium of  esophagus  is not only
seen before the development of invasive  malignancy but also in
the areas adjacent to the squamous cell carcinoma . A similar
situation is seen in adenocarcinoma which shows glandular
dysplasia.  Intestinal metaplasia seems have the highest risk.
Also, the risk of cancer increases with increasing grade of
dysplasia.  As  of now it is not clear  how a  high grade dysplasia
behaves because  both stable disease  and  malignant change have
been described
• Areas of  frank malignancy  are found in almost  half of the
patients  with Barret’s esophagus  with high grade dysplasia. So
most physicians  consider resection a better option  so that  all the
above patients are cured .
•
9• An Inverse association  is noted between GE junction
adenocarcinomas and Helicobacter pylori infection  and
antioxidant intake while  these factors had no convincing
association with gastric adenocarcinoma.
• Numerous genetic alterations  have been implicated in the
carcinogenesis of  gastroesophageal junction carcinomas. Often
significant aneuploidy is noticed. In the evolution of  esophageal
carcinoma , the tumor suppressor gene P53 is affected in the
initial stages itself.
•  In patients with Barrett metaplasia  , the occurrence of
malignancy has been linked to the above derangement. Over
expression  of P53 precedes aneuploidy. In a study by Gomes  et
al differences have  been noted in gene expression profiling
among adenocarcinomas of oesophageal, OGJ and gastric origin.
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Clinical presentation
Many of the patients are known to present with dysphagia . To
produce dysphagia the tumor  has to narrow the esophageal lumen to less
than 12mm or  occupy at least two-third of the circumference.  Upper
abdominal pain  which is usually vague along with dyspepsia may be the
only symptom in some patients. So all people more than 45yrs and new
onset dyspepsia should have an upper GI endoscopy done. A small
percentage of tumors have odynophagia. Occasionally, patients may have
respiratory symptoms like cough and  dyspnea  due  to aspiration
following obstruction. In case of locally advanced disease some patients
may complain of  back pain.
Examination
In early cases physical examination is usually unrewarding. When
the mass   is palpable transabdominally the cancer  is usually inoperable. In
advanced  disease, one may find an  enlarged supraclavicular  lymphnode,
pleural effusion, hepatomegaly with secondaries in the liver , ascites or
pelvic deposits.
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Lymph node stations:
AJCC                            AJCC Japanese
The lymphnode station numbers  for esophageal and GE junction
cancer by the Japanese  is an extension of gastric cancer lymph node
station there by avoiding number repetition.
STAGING:
Staging tumors  in the region of  gastro esophageal junction, was an
area of contention in the past. But  the current staging manual for cancer of
esophagus also includes the gastroesophageal junction. The seventh edition
AJCC staging system for esophageal cancer harmonizes cancer staging
across the esophagogastric junction.
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One major modification in the seventh edition of AJCC/ UICC is
reclassification of N stage. The sixth edition defined regional nodes for
thoracic esophageal cancer as those in the periesophageal, mediastinal, and
perigastric areas (N1 disease), but cervical and celiac nodes were regarded
as “distant”. The N stage  in th 7th edition has been similar to that used in
carcinoma stomach in which the number of nodes determine the stage
rather than the location of the node .Thus tumors across the
gastroesophageal junction are  uniformly  grouped.
In the current system, the site of origin of  the tumor, the grade of
tumor  and histologic  type was considered to affect the prognosis in early
stages only.
The subdivisions in the  M stage which was previously present have
been removed and  only the presence or absence of distant metastasis was
noted.
Investigation
BARIUM CONTRAST STUDY
Barium  upper GI contrast study contrast study shows mucosal
irregularity and shouldering, proximal dilatation and luminal narrowing. It
helps in assessing the longitudinal extent of growth on  the esophageal side
BARIUM SWALLOW
CECT ABDOMEN
CECT ABDOMEN
CECT ABDOMEN
CECT ABDOMEN
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and along the lesser and cardia of stomach. Presence of the entire lesion
below the diaphragm helps in surgical decision making. Streaking of
barium  outside the esophageal lumen in an asymptomatic patient indicates
contained perforation which may be spontaneous or iatrogenic due to
previous endoscopic procedure. In cases with extension into the middle
third of esophagus, it helps to know the relation of tumor to the mediastinal
structures like trachea and bronchi .Signs like tortuosity,  angulation, axis
deviation from midline, sinus formation and fistula formation with the
bronchial tree indicates that the tumor has crossed the adventitia and
involved the  neighboring structures.
ENDOSCOPIC EXAMINATION
Upper gastrointestinal endoscopy and biopsy  is the primary
modality used for  diagnosing gastroesophageal junction tumor .It helps in
assessing the  mucosal  extent of disease-vertical and circumferential
,degree of involvement of stomach in the cardiac region and on the lesser
curve side. The presence of satellite lesions are also noted which helps in
planning the extent of esophageal resection and proximal margin. It
however misjudges the vertical extent of tumor in a case of  submucosal
extension of  tumor.
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Based on endoscopic examination superficial tumors are classified as
Type 0 to 1:superficial and protruding
Type 0 to II:superficial and flat
Type 0 to III:superficial and distinctly depressed
Based on this endoscopy advanced tumors are classified as
Type 1 :localized protruding
Type 2:ulcerative and localised
Type3:ulcerative and infiltrative
Type 4: diffusely infiltrative
Type 5:miscellaneous
BRONCOSCOPY
Broncho scopy   is done to see  the involvement of the
tracheobronchial tree by the tumor particularly by the tumors of upper and
middle portions of the esophagus and is usually not required in a GE
junction tumor  unless the middle third of esophagus is involved
contiguously. Widened  carina ,external compression, tumor infiltration
and fistulization are the sings of involvement of trachea bronchial tree.
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Tumor infiltration and fistulization are the contraindications for resection.
Biopsy and brush cytology are also  done in suspicious cases
ULTRASOUND ABDOMEN
In cases of adenocarcinoma of the GE junction as there is a high
possibility of advanced disease , ultrasound abdomen helps in detecting
liver metastasis , ascites  and extensive abdominal lymphadenopathy, thus
obviating the need for further investigation by expensive modalities.
CT SCAN
CT scan is done for most  patients with GE junction tumors . It helps
in detecting  distant metastasis. It also helps in evaluating the local extent
of disease. Thickening of esophageal wall of more than 5 mm is abnormal .
The anatomical details  that a surgeon needs before surgery can be well
delineated in a good quality CT of the chest and CT of the abdomen.The
CT has to be done with  the contrast given  intravenously as well as by oral
route. Loss of fat plane between the esophagus and the aorta, trachea and
bronchi and the pericardium is suggestive of  invasion, but absence of fat
in a thin patient  makes this criteria unreliable. The accuracy of CT for
aortic infiltration is 80%when the area of contact between aorta and
esophagus is more than 90 degrees of circumference of aorta. The
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sensitivity in diagnosing  T4 disease  was 25% . The specificity in
diagnosing T4 disease  was 94% .A multislice CECT with coronal and
sagittal reconstruction  may dispel  the need for a barium swallow  by
providing similar information.
LAPAROSCOPY
Laparoscopy  is the best modality  in  detecting  peritoneal  disease.
Therefore before proceeding with laparotomy, a staging laparoscopy is to
be done  especially in a case of adenocarcinoma of gastroesophageal
junction. It avoids noncurative  laparotomy  in  11%–48% of patients.
PET  and PET-CT:
PET-CT  is the most accurate noninvasive modality for detecting
M1  disease  .In  as  study  by  Roedl  et  al,  PET-CT  was  shown  to  be  more
accurate than PET in characterizing the distant metastatic sites of
gastroesophageal junction carcinomas. On combining the visual
interpretation with tumor volume measurements, the PET-CT has a
sensitivity of 96% . The specificity of PET-CT is 94% . PET-CT helps in
detecting the response to neo adjuvant therapy
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ENDOSCOPIC ULTRASOUND
EUS forms an important modality of evaluation for assessing the
local extent of the disease. EUS is generally  performed after staging CT,
which may detect distant metastases or direct the EUS to specific
abnormalities needing clarification. The accuracy of staging with radial
and linear echo endoscopes   is equivalent and either type of instrument is
suitable for staging. Details of metastases like  involvement of  right and
left lobe of liver or left adrenal can be  noted . FNAC or  biopsy could be
performed as required  . It also helps in identifying  longitudinal sub
mucosal spread not visible at upper GI endoscopy. The upper and lower
margin of the tumor from incisor teeth and aortic arch is noted. The
distance of the upper or lower edge of tumor from gastro esophageal
junction  and whether  the gastroesophageal junction is involved is noted.
Accuracy for T & N stage is approximately 80-85% and 60-70%
respectively. T1m (mucosal), T1sm (sub mucosal)
T2 - For type 3 junctional tumors  T2a = breaches muscularis  propria;
                                                         T2b = breaches subserosa.
T3 (minimal – i.e. tumour just breaches muscularis propria, 4th layer)
      (bulky – i.e. extensive invasion of muscularis propria but not T4)
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T4a - Involvement of  pleura, diaphragmatic crura, pericardium,
T4b- Involvement of , , aorta, bronchus, carina, trachea or other
irresectable structures.
?  Involved nodes may be recognized by established EUS criteria (size >
1cm, hypo echoic, well demarcated and round) – if all 4 criteria are
present the probability of malignancy is around 80%.In staging  lymph
node ,the total number  of  lymph nodes identified, location of  nodes
and whether  FNAC was  performed is  noted.
Major complication rate for staging EUS  with or without FNA (
bleeding, perforation, infection ) is usually  less than 1%. FNA samples
have diagnostically adequate cellularity in about 90%.  There are echo
endoscope that can traverse tight strictures and dilatation of a tumor for
EUS is not advisable .If  dilatation is planned, it is to be first discussed
with the the surgeon who is likely to be undertaking surgery in case
perforation occurs and emergency surgery is required. Presence of full
thickness tumor below diaphragm is noted as it helps in planning
appropriate surgery.
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Treatment
SURGERY
For these patients who are surgically fit  and in whom distant
metastasis has been ruled out , resection is the main modality  of treatment.
Long term survival in these patients is dependent on   Ro resection  status
as  well as the T and N stage. As these tumors spread  submucosally
planning  the longitudinal extent of resection is considered to be
problematic. Involvement  of  vital adjacent organs like the aorta make
these tumors irresectable.
Access:
Since the Gastroesophageal junction tumor   is located at the
crossroads of   abdominal and thoracic cavities, may  be  accessed from
either  ways or    by using both of them. It also depends on where the bulk
of tumor lies in relation to diaphragm.The  various options are listed below
Abdominal-In most tumors  the bulk of it lies on the abdominal side
as in the case of siewert type 3, making this approach  the commonest  one
used. A total gastrectomy which is the procedure of choice for both siewert
type 3 and most siewert type 2  cancers is  comfortably done from the
abdominal side by either a midline or using a bilateral subcoastal incision.
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Also most Gastrointestinal surgeons are comfortable operating from  the
abdominal side. Even for Total or subtotal esophagectomy as  in a case of
siewert type I tumor or Squamous cell carcinoma of the lower end of the
esophagus, a transhiatal esophagectomy would  avoid a  thoracotomy and
its sequelae.
Thoracic approach- Trans-thoracic esophagectomy (TTE) can be
done by the classical Ivor lewis method involving right thoracotomy.
A limited  distal esophagectomy with proximal or   total gastrectomy
can be done  by a thoracoabdominal  incision   on the left side.
TYPE AND EXTENT OF SURGERY
• Siewert Type I tumors
          - requires Esophagectomy   similar to that of squamous cell
carcinoma.
              What ever may be the approach. transthoracic  or transhiatal  the
lower mediastinal lymphnodes have to be removed.
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For Siewert Type 2 tumor the options  include
• Left thoracoabdominal approach ,
• Proximal gastrectomy + Subtotal esophagectomy
(Laparoscopy/VATS) ,
•  Total gastrectomy with transhiatal distal esophagectomy
• Right Ivor lewis  approach and using either the stomach or the
jejunum for restoring intestinal continuity .
Patient factors such as pulmonary function, body habitus and  prior
surgery are important in selecting the appropriate surgical approach. Each
approach has its advantages and disadvantages and  no single option has
demonstrated a clear survival benefit over the others provided that an
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adequate lymphadenectomy has been done and  adequate margins are
obtained . Bile reflux esophagitis can be a difficult problem to manage if
reconstruction includes an intrathoracic esophagogastrostomy, while
complex reconstructions with colon or jejunal interpositions carries  an
even higher morbidity rate. Hence most  surgeons attempt to place the
esophagogastric anastomosis in either the abdomen or neck and use the
gastric remnant as the conduit of choice .
To ensure clear margins, intraoperative frozen sections should be
used liberally . But, even frozen section can lead to false-negative results.
In  a   study  by  Ito  et  al.,  a  recommendation  was  made  to  achieve  a  gross
proximal resection margin length of at least 6 cm and a distal resection
margin length of at least 4 cm, regardless of tumor location. There are  two
caveats: first, that the degree of mural extension by gastric cardia
adenocarcinomas is strongly correlated with T stage, and second, that
margin lengths reported in their study were measured on prefixed fresh
specimens immediately after resection. Therefore , intraoperative decisions
should be made based on margin length requirements that may need to be
significantly greater than those derived from postresection specimens
which is more  pertinent to T3 and T4 tumors .
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LYMPHADENECTOMY.
Lymph nodes in the lower mediastinum are involved in up to 40% of
cases  of siewert type 1 adenocarcinoma and in 2.5% of  cases of  siewert
type 2 adenocarcinoma. However, the majority of positive nodes
associated with Siewert type II and III cancers involve the  left gastric,
lesser curve and  paracardial nodes , which are included in both abdominal
and thoracic approaches and the incidence of lymph node positivity is not
influenced by the surgical approach.  Theoretically, D2 dissection ,  have
the advantage of  removing the entire lymph node basin thereby decreasing
the rate of local recurrence.
• Only patients  with pN0 and pN1 have the chance for cure
• Even though  the superiority of   extensive lymphadenectomy has
not been proven , it provides a more accurate pathologic staging.
Most patients  usually succumb to a distant metastasis at some point
of time. The recurrence in the lymphnode stations located  in the para
aortic region  which are not removed in a D2 dissection.
PERFORATION
Iatrogenic perforation of cancer of the gastroesophageal (GE)
junction is a potentially life-threatening complication. Its incidence has
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increased most likely because of more aggressive palliative endoscopic
therapy, and the current widespread use of endoscopic ultrasound (EUS)
for accurate preoperative staging. Irrespective of the treatment, iatrogenic
(or spontaneous) perforation of the tumor dramatically decreases  long-
term survival. Therapy should therefore focus on the immediate and
efficient control of the perforation (such as drainage, stenting or resection),
and on a satisfactory quality of life rather than on oncologically adequate
treatment. The approach of conservative versus surgical therapy in cases of
iatrogenic perforation has shifted more towards conservative therapy,
together with the development of novel endoscopic stenting possibilities.
However, under certain conditions, the conservative approach is not
feasible; e.g., the perforation is too extensive for adequate stent therapy, or,
if  the tumor is (subtotal) stenosing, making successful stent therapy
exceedingly difficult in which case a  limited resection of  GE junction and
esophagogastric anastomosis could be attempted in selective cases. Other
indications for a surgical approach include extensive peritonitis or
mediastinitis that cannot be drained adequately by interventional drainage
placement. There are two large studies addressing this issue have favored a
conservative approach . Di Franco et al  have examined 48 patients with
iatrogenic perforation of esophageal cancer. Sixteen patients were treated
by oncological esophagectomy, and 32 were treated conservatively
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because of advanced disease in 17 and poor performance status in 15. They
demonstrated that all patients in the resection group died of recurrent
disease and more than half of them died within the first year after surgery.
There was no significant difference in the survival between the resected
and non-resected group of patients. In an another study,  Jethwa et al have
analyzed 83 iatrogenic perforations during diagnostic endoscopy, of which,
27 were managed by surgery. The median survival in the whole cohort was
72 d. There was a trend for longer survival in patients undergoing surgery.
However, the high 30-d mortality of nearly 40% and the poor survival in
the surgical and non-surgical group shows that even rapid surgical
treatment often fails to change the natural course of the disease at this
stage.
Neoadjuvant  chemotherapy/chemoradiotherapy:
The relatively small randomized trial from Ireland comparing
preoperative chemoradiotherapy (cisplatin and 5-FU) reported a significant
improvement in overall survival at 3 years, and a decrease in regional node
involvement at the time of surgery. However, this study has been criticized
for the relatively short duration of median follow-up (10 months) and the
unexpectedly low overall survival in the surgery alone arm.
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In  a  meta-analysis   of   11  RCT’s    by  Kaklamanos  et  al.   an
improvement in the 2-year survival compared with surgery alone was
noted. An absolute difference  in the survival  of  6.3% was noted when the
four most recent studies were analyzed. Treatment-related mortality did
increase by  1.7% for patients with Neoadjuvant chemotherapy and 3.4%
for patients with Neo Adjuvant chemoradiotherapy  .
Recent  studies verifying the role  of   neoadjuvant
chemoradiotherapy  have shown  a survival advantage  for
adenocarcinoma  rather  than a  squamous cell carcinoma  of  the
esophagus .
• The ISDE/IGCA consensus conference recommended that
neoadjuvant therapy be restricted to patients with locally advanced
tumors of the esophagogastric junction where an R0resection is
questionable.
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Adjuvant chemotherapy and chemoradiotherapy
As these patients have high rate  of  systemic failure ,all the  node
positive patients post R0 resection are subjected to adjuvant therapy. The
US GI Intergroup trial (INT 0116) has provided the best data to date in
support of adjuvant chemoradiotherapy. Postoperative chemoradiotherapy
improved overall survival by 9% at 3 years and nearly 20% at 7 years..The
conclusion in the intergroup trail was  that postoperative
chemoradiotherapy is slowly emerging as the standard of care in treating
gastric cancer and  GE junction cancers and future areas of research were
needed to evaluate new chemotherapeutic agents and improved modalities
of radiation delivery and identify molecular markers that may indicate
patients who are more likely to benefit from adjuvant therapy .
Multimodality therapy
Optimal treatment of these tumors using multiple modalities has yet
to be established by prospective, randomized control trials. Siewert’s
classification  has been used to evaluate the pattern of lymphatic spread
and evaluate outcomes after surgery. Apisarnthanarax and Tepper used the
Siewert classification system to review randomized controlled trials of
esophageal and gastric cancers. There were nine studies of esophageal
and/or gastric cancer  that included patients with a diagnosis of GEJ
28
tumors. The studies were considered most relevant if the trials included
only patients with adenocarcinomas.
Only five of the nine studies  included information on the number of
patients with GE junction tumors. Among these, the authors concluded that
only three were most relevant to the management of GE junction tumors;
namely, the United Kingdom Medical Research Council MAGIC trial, the
US Gastrointestinal Intergroup INT 0116 trial and a trial from Ireland of
multimodal therapy and surgery for esophageal cancer.  MAGIC trial
involved the  study of perioperative chemotherapy with ECF (5-
fluorouracil [5-FU],epirubicin, cisplatin,) vs  surgery alone for cancers of
the  stomach, gastroesophageal junction and  lower esophagus. GE
junction tumors comprised 12% of these tumors. They  reported an overall
increase in 5-year survival from 23% to 36% with perioperative
chemotherapy compared with surgery alone. The rate of distant metastasis
reduced from 37% to 24% with chemotherapy, while the  curative
resection rates were not improved. Patients with GE junction cancers rather
than lower esophageal adenocarcinomas appeared to derive the most
benefit in  the subgroup analyses, based on hazard ratios. A significancant
improvement  in  survival  favoring multimodal therapy was reached at 3
years in the inter group trail.
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TARGETED THERAPY
While recommendations regarding the use of targeted therapies in
the management of GE junction carcinomas await the completion of
randomized trials, there is good reason to remain optimistic based on the
recently reported phase II studies . Bevacizumab is a humanized
monoclonal antibody targeting (VEGF)vascular endothelial growth factor
.  Bevacizumab  binds VEGF  which is a potent stimulator of angiogenesis
that is often expressed in many solid tumors  and blocks it from binding to
its receptor located on endothelial cells. Bevacizumab was well tolerated
in the phase II studies and was not associated  with increased treatment
related  toxicities . In two  studies, the response rates was  more than
60%. Epidermal growth factor receptor (EGFR) activity inhibitors are also
widely employed in cancer  treatment. EGFR activity is frequently
increased in many cancers, including GE junction , promoting cell
survival, tumor cell growth and proliferation. Therapies directed at
inhibiting EGFR activity include antibodies that block ligand binding
(cetuximab) as well as small-molecule inhibitors of the EGFR tyrosine
kinase domain (gefitinib and erlotinib, among others).In phase II studies
,toxicities associated with these drugs were no different from those
observed in other trials. Some modest efficacy was observed  whether used
as single agents or in combination with other chemotherapeutic drugs.
Multimodality treatment  using  a combination  of  surgery,
chemotherapeutic agents, radiotherapy and biologic therapies  appear to be
promising .
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MATERIALS AND METHODS
All the patients presenting to our department(surgical
gastroenterology) at Rajiv Gandhi Government General hospital from
august 2010 to February2013 with gastroesophageal junction tumors  or
those presenting  with  dysphagia and  regurgitation  and on  evaluation  by
upper gastrointestinal endoscopy and imaging studies,  found to have
gastroesophageal junction tumors  and distant metastasis ruled out by a
CECT were studied.
Age, gender, chief complaints, co-morbid illness, nature of diet,
personal habits like   smoking and alcohol consumption were  noted.
Complete  physical examination  findings of the patients  like  presence or
absence of  jaundice, pallor, pedal edema and bilateral  supraclavicular
lymphadenopathy  if  any were noted. Abdominal examination  was  done
to look for any palpable mass, hepatomegaly  and free fluid. Rectal
examination was  done in all patients  to rule out  pelvic deposits. Lab
investigations including a complete hemogram, liver function tests and
renal function tests  were done.
Coagulation profile was also done. Diagnosis was established by an
upper GI endoscopy and biopsy. After distant metastasis  was ruled out by
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chest X-ray and ultrasonogram of  abdomen , contrast enhanced
computerised tomography of chest and abdomen was done  for all patients.
Endoscopic ultrasound  and PET were  not  done in any of our
patients . If the patients are suspected to have  advanced disease , staging
laparoscopy  was done . Eighty one  patients with gastroesophageal
junction tumors were  included in the study . Consent was obtained from
all the patients explaining the nature of illness ,the possibility of  finding a
distant metastasis, the various modalities of treatment and their efficacy ,
the  morbidity and mortality associated with the disease and the surgical
procedure. The performance status of the patient  was  assessed  and the
cardiorespiratory status evaluated. Hydration status, nutritional status and
coagulation profile were noted and corrected in case of derangement.  All
patients were encouraged to have incentive spirometry   before surgery.
For patients with, poor performance status i.e ECOG-4 and severe
malnourishment, a nasogastric tube was passed , if the lesion has not
caused complete obstruction for improving the nutrional status. The type of
surgery  was planned  based on the histopathological report,  the location
and extent of disease. Staging laparoscopy was done in all cases of
carcinoma of gastroesophagel junction before proceeding with definitive
surgery.
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During the  definitive surgery, the  abdomen is opened by a midline
incision  and operability is ascertained  once again  before  resection is
proceeded with.
For all cases of squamous cell carcinoma  involving GE junction and
Siewert type 1 adenocarcinoma ,transhiatal esophagectomy(THE) was
done  .As our department’s protocol  is to do a transhiatal esophagectomy
for all lower third esophageal carcinomas ,the above group including
Siewert type1 adenocarcinoma were  treated by THE which also include
the removal of lower   mediastinal lymphnodes transhiatally undervision
after widening of the  hiatus.
          Following  THE reconstruction was done using a stomach tube
created  along the greater curvature  based on right  gastroepiploic pedicle
by stapling  along  the lesser curve side. The neck is opened by a left
oblique  incision along  the anterior border of  sternomastoid and  the
esophagus is mobilized. Retractors are not applied on the medial aspect  of
neck wound  thereby  avoiding  injury  to the recurrent laryngeal nerve.
Esophagogastric anastomosis was done in the neck by either a completely
handsewn technique or by a stapler  .
TRANS HIATAL ESOPHAGECTOMY SPECIMEN
PREPARING STOMACH TUBE
NECK ANASTOMOSIS
ESOPHAGOJEJUNAL ANASTOMOSIS FOLLOWING TOTAL
GASTRECTOMY
STAPLED  ANASTOMOSIS USING CIRCULAR STAPLER
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          In the partial stapling technique , linear cutter was used for creating
the posterior esophagogastric conduit anastomosis, while the stapler rent
anteriorly was closed by a  handsewn technique(stapled side to side
esophagogastric conduit anastomosis). The  above  could also be done as a
totally  stapled technique by firing another stapler to close the anterior
anastomotic rent similar to the  double stapled  technique used to create a
small bowel anastomosis .  Alternatively a circular stapler no.25 was used
in some cases to perform the esophagogastric conduit anastomosis in the
neck.
For Siewert type 2 tumors , a total gastrectomy with D2 lymphnode
dissection+ transhiatal resection of the distal esophagus with adequate
margin  was  done.
For Siewert type 3 tumors , a total gastrectomy with D2 lymphnode
dissection was  done. The duodenal  stump  in case of  total gastrectomy
was secured  using  a stapler usually  a linear cutter(TLC-55). The
esophagojejunal anastomosis was done in a end to side fashion either by
using a circular stapler  or  by a  hand sewn technique.
 In all the patients post resectional surgery, a feeding jejunostomy
was done  by modified witzel technique using a no.12/no.14F suction
catheter. Broad based fixation of the tube to the abdominal wall was done.
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The feeding jejunostomy not only  helped  in starting  early enteral
nutrition in the  post operative period  but  also  provided enteral feeding
access  for patients with  a leak.
Intra operatively ,the duration of surgery, blood loss,  blood
transfusion, the technique of  anastomosis -whether a linear or circular
stapler was used or whether it was a done by a completely handsewn
technique was noted.
Post operatively ,the need for  ventilator support, the day of
extubation, the day of removal of nasogastric tube, drainage tube  and
whether an intercoastal chest drainage tube was inserted   was noted.
All the patients  had  their epidural catheter removed on the 2nd post
operative day. The urinary catheter  was removed on the third
postoperative day unless the patients required intensive monitoring. The
integrity of the anastomosis was checked by a gastrograffin study on the 7th
postoperative day.
A chest X-ray was taken on the  day of surgery post operatively to
look for the presence of  adequate lung expansion in patients who
underwent THE and  ICD insertion  and in cases where pleural breach was
suspected intra operatively.
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The length  of postoperative stay was noted along with major
complications like  anastomotic  leak, intra-abdominal collection and other
minor complications like wound infection, respiratory complications, and
urinary tract infection. All the complications after the operative procedure
including mortality were  noted .
Anastomotic  leak
Neck
Drainage of significant amount of pus followed by  saliva  or
drainage of orally ingested substance or demonstration of contrast
extravasation on contrast study is noted as anastomotic leak in the neck
Adbominal
Drainage of  bilious fluid  or intestinal contents through the
abdominal drain or through the abdominal  wound or a significant intra
abdominal collection of pus or intestinal contents or leak requiring
radiological or surgical intervention is noted as intra abdominal
anastomotic leak.
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Intra-abdominal collection
Any collection detected by ultrasonogram or CECT of more than 5
cm is noted as intra abdominal collection and planned for percutaneous
aspiration followed by drainage if necessary.
Haemorrhage
Bleeding complication following  surgery requiring monitoring,
transfusion, radiological and surgical intervention were noted.
Wound infection
Collection of fluid or pus  at the operative  site with erythematous
wound edges with or without  fever, leucocytosis and in the absence of any
major complications is noted  as wound infection. It was managed by
letting out the pus or fluid, sending it for culture and sensitivity treating
with appropriate antibiotics.
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Respiratory  complications
         Most patients have epidural analgesia which  helps in  early
ambulation and aggressive pulmonary toileting with chest physiotherapy
.All these  patient are encouraged to do respiratory exercises with  triflow
incentive spirometry.  All post-operative patients  with fever and
diminished air entry or other lung signs  are noted to have  respiratory
complication.
Urinary Tract Infection
Patients with burning micturition  with fever  and positive urinary
culture and no other identifiable source are noted to have urinary tract
infection. They are treated with hydration and antibiotics.
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RESULTS
Of  all the patients with gastroesophageal junction tumors, those
patients  who were found to have distant metastasis or locally advanced
disease by imaging were referred to palliative chemotherapy,
chemoradiotherapy  or palliative supportive care and were excluded from
the study. Also patients with proximal gastric cancer within 5cm of
gastroesophageal junction but not involving the gastroesophageal junction
and those with esophageal carcinoma  5cm proximal to gastroesophageal
junction and those not involving the gastroesophageal junction were
excluded from the study. 81 patients who had  resectable  disease on
imaging  in whom surgery was  planned were studied.
STATISTICAL ANALYSIS:
The data collected in the proforma were entered in an excel sheet of
Microsoft Office software and inference obtained after statistical analysis.
The mean and standard deviation and  proportions were computed where
ever necessary.
The age of affected patients  ranged from  20- 77yrs.The median age
was 55yrs while the mean age was 51.9 yrs  with a  standard  deviation  of
12.26.
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From the above chart it is evident that most of patients  are  between
40-65yrs.Of the total 81 patients studied , there were  51 males  and  30
females.   The males  were 1.7 times more commonly involved than
females amounting to63%  of  total cases.
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Symptoms:
33(40.7%) patients  had  upper abdomen pain ,while  dysphagia was
the commonest  symptom  present in 64(79%)  patients.  Hemetemesis was
present in 7 (8.6%)patients and  malena was present in 9 (11.1%)patients.
.
History of heart burn was present in 40(49%)patients. Loss of
weight  was present in 60 (74%) while loss of appetite   in 59(72.8%)
patients .The  patient with  leiomyoma  was completely asymptomatic and
the tumor was detected incidentally  during a routine checkup that was
mandatory before  joining a institution for academic studies.
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Hypertension was present in 11patientsand diabetes was present in 8
patients.3 patients had coronary artery disease while 18 patients  had
COPD.
Co-morbidities
Hypertension 11(13.5%)
Diabetes 8(9.8%)
Coronary arterydisease 4(4.9%)
Bronchial asthma 1(1.2%)
46 patients(56.8%) had association with cigarette smoking and
35patients(43.2%)had association with alcohol abuse while tobacco
chewing was associated with 28patients(34.5%) . Only 3patients were
vegetarians  while the remaining 78 were non-vegetarians
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The most common histopathological diagnosis was adeno-
carcinoma found in 69(85.2%)patients, followed  by squamous cell
carcinoma in 7(8.6%)patients. Gastro intestinal stromal tumor was seen  in
3(3.7%)patients , basiloid squamous cell carcinoma in 1 patient and
leiomyoma  in 1patient.
Of the 69 patients with adenocarcinoma , the distribution among
siewert classification is as follows. Siewert type 1 adenocarcinoma was
found in 5 patients while siewert type 2 adenocarcinoma was found in  27
patients and siewert type 3 adenocarcinoma was found in 37 patients.
siewert type 1 5(7.2%)
siewert type 2 27(39.1%)
siewert type 3 37(53.6%)
HPE
sq.cell ca.
GIST
adeno ca.
leiomyoma
basiloid scc
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Grade of differentiation
 In the study group, excluding the 3 patients with GIST and 1patient
with leiomyoma ,20(25.9%)patients had   well differentiated tumor , while
32(41.5%)patients  had  moderately differentiated tumor  and
25(32.4%)patients had poorly differentiated tumor.
DIFFERENTIATION
Well differentiated 20(25.9%)
Moderately  differentiated 32(41.5%)
Poorly  differentiated 25(32.4%)
3 patients with GIST and 1patient with leiomyoma had an exophytic
growth.  The gross appearance of  the  remaining tumors  was  protruding
type  in 36(46.7%)patients , while in 23(29.8%)patients it was an
ulcerative lesion  and in 18(23.3%)patients , it was infiltrative in nature.
GROSS APPEARANCE
Protruding type 36(46.7%)
Ulcerative 23(29.8%)
Infiltrative 18(23.3%%)
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Curative surgery
45patients (55.5%) were operable and underwent resectional surgery
while 36patients(44.5%) underwent palliative treatment. Of the patients
who underwent resectional surgery, the variables are summarized below.
The day of ryle’s tube removal , drain removal and oral intake was noted .
Minimum Maximum Mean
Standard
deviation
Age(yrs) 20 77 50.6 12.6
Hb(g%) 6 13 8.86 1.26
Albumin(g/ml) 2.5 4.2 3.3 0.3
Duration of
surgery(min)
160 410 254.4 60.8
Blood loss(ml) 100 520 216 87.2
Ryle’s tube
removal
6 22 7.92 2.21
Drain removal 3 22 7.7 2.95
Oral intake 6 20 7.97 2.56
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The average  age of the patient undergoing resectional surgery is
50.6yrs.The mean haemoglobin and albumin values were 8.8g% and
3.3g% respectively. The average duration of surgery was 254 minutes
while that of  blood loss was 216ml.The time of  removal of the ryle’s
tube, drain tube and oral intake is around the 8th postoperative day.
Among the patients who underwent resectional surgery,11(24.4%)
patients had wound infection while 6(13.3%) patients had respiratory
complications.
The average post operative stay was 9.58 days in all patients, with a
standard deviation of 4.58.The feeding jejunostomy  done in resected cases
was retained until the completion of chemotherapy and in 3patients who
had their  feeding jejunostomy  during trial dissection for unresectable
tumor  was retained  for feeding access.
Totally 45 patients underwent surgical resection with a curative
intent in which 29 patients underwent total gastrectomy while 13 patients
had Transhiatal esophagectomy,  2patients had proximal gastrectomy and
one patient had proximal gastrectomy+distal esophagectomy . 3 patients
underwent  feeding jejunostomy  for feeding access after they were found
to  be irresectable  by trial dissection. All these patient  had underwent
neoadjuvant  treatment before surgery.
46
Post operative ventilator support was required in 2 patients, of
whom one was extubated on the same day  of surgery while the other was
extubated on the second postoperative day.
Proximal gastrectomy was performed   in  3 patients totally- 1
patient with leiomyoma  ,one patient with GIST and one patient with
siewert type 2 adenocarcinoma underwent proximal gastrectomy+ distal
esophagectomy .
Total gastrectomy was done in 29patients overall,  of whom one
patient underwent metastatectomy  of  a solitary metastasis  in the leftlobe
of liver  along with total gastrectomy while  the other had distal
pancreatectomy +splenectomy for locally advanced siewert 3
adenocarcinoma.
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All the patients with a  histologic  diagnosis of  squamous cell
carcinoma , basiloid squamous cell carcinoma and siewert type 1
adenocarcinoma were subjected to Transhiatal esophagectomy  totaling to
13 in number.
Histopathology THE
Squamous cell carcinoma 7
Adenocarcinoma- siewert type-1 5
Basiloid squamous cell carcinoma 1
Total 13
Of the 13 patients who underwent THE, a completely  handsewn
anastomosis was done in 5 (38.4%)patients, while a stapler was used in the
remaining 8(62.6%). In the stapled anastomosis, 5 of 8 had partial
posterior stapling with linear cutter and anterior handsewn , while  3 of 8
stapled patients had a circular stapled esophagogastric anastomosis. The
posterior stapling technique(side to side stapling using linear cutter) is
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believed to provide a wide anastomosis  thereby decreasing the possibility
of stricture formation even in case a leak occurs.
Neck leak occurred in two patients patients  which settled with
drainage  and nutritious feeding through the feeding jejunostomy tube in
one  patients  while the other  patient died due to aspiration pneumonia . In
the 2 patients who had neck leak, the esophagogastric conduit anastomosis
was done by a completely handsewn technique in one patient and by a
stapled technique in other patient.
R0 resection was achieved in all patients except  one  who had R1
resection. This patient had a siewert type 2 adeno carcinoma.
Overall  33 patients were found to have distant metastasis. Staging
laparoscopy  done in all patients with adenocarcinomas helped in
identifying metastatic disease like peritoneal deposits, omental deposits or
small surface liver nodule .In 33(40.7%) patients a staging laparoscopy
helped in avoiding a laparotomy and were referred to palliative
chemoradiotherapy .Patients with impending obstruction were referred for
stenting.
3 patients were referred for surgical treatment  following  absence of
response to Neoadjuvant treatment. Of  these 2 had undergone
chemotherapy and one patient underwent  chemoradiotherapy. All the 3
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patients  were inoperable   on trial dissection and had  only a feeding
jejunostomy  done.
Following total gastrectomy, in 8 (27.6%)patients  the
esophagojejunal anastomosis was done  by  a hand sewn technique  while
in 21 (72.4%)patients  it was done  using SDH 25 circular stapler.
 Two  patients  had  esophagojejunal anastomotic leak  following
total gastrectomy .Among these two leaks, 1 was   hand sewn anastomosis
while the other was a stapled anastomosis. One  of the above  patients had
esophagojejunal anastomotic stenting while  the other  patient had
coronary artery disease  and  underwent percutaneous image guided
drainage .
All the patients  who  had  resectional surgery underwent adjuvant
chemotherapy excluding  those who succumbed postoperatively. Patients
who had a  leak or were poorly nourished were advised to attend
chemotherapy schedule after  healing of the leak  or after two weeks.
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Staplers
Staplers were  used in 40 out of 45 patients who underwent
resectional surgery.
Only in 5 patients  who had THE and reconstruction by a completely
handsewn technique  was the stapler  not used. Even in those patients who
underwent reconstruction of esophagojejunal anastomosis by a handsewn
technique, the duodenum was secured and divided with a stapler.
Stricture occurred in one patient following a neck leak. The
esophagogastric conduit  anastomotic stricture  was relieved by dilatation.
During the  follow up period of 31 months , 37 patients  who
underwent  resectional  surgery  were  alive  .Out of the above ,1 patient
had recurrence in the gastric conduit detected by endoscopy.8 patients
were lost  to follow up.
Blood transfusion
Overall 23 (28.4%)patients  required  blood transfusion in the study
group of 81 patients. Of the 45 patients who underwent  resectional
surgery, 7(15.5%) patients required  blood transfusion. In these patients
post operatively transfusion was done to maintain a haemoglobin of 10g%
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Mortality
Two patients  in the study group died postoperatively. This accounts
for a mortality of 2.4%  of  all patients and  4.4% when the denominator
was the number of  patients who  underwent resectional surgery. One of
these patients had undergone a total gastrectomy while the other one
underwent a transhiatal esophagectomy. Both  the  patients had coronary
artery disease.
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DISCUSSION
In the  study group, males were more more commonly affected than
females accounting for 63% of cases. 56.8% had association with cigarette
smoking and 43.2% had association with alcohol abuse while tobacco
chewing was associated with 34.5% of patients. History of heart burn was
present in 49%.
Adenocarcinoma  was the most common histologic type found in
85.2% followed by squamous cell carcinoma in 8.6%.Three patients had
gastro intestinal stromal tumor while 1had leiomyoma.
This shows that  there is a rise in the incidence of adenocarcinoma
around gastroesophageal junction in the  geographical location of the study
i.e South India similar to that observed in the western population.
Dysphagia was the most common symptom present in 79%. Loss of
weight was present in 74% of patients while loss of appetite was present
in72.8%.Co-morbidities were present in around 15% of patients.
Most of the patients presented  in the advanced stage of disease i.e
either stage 3 or 4. A little more than half of the patients were operable.
Staging laparoscopy helped  in avoiding  nontherapeutic  laparotomies in
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40.7% of  cases while it did not avoid laparotomy in three patients who
underwemt trail dissection..
Total gastrectomy  was the most common  resectional surgery done
(in 64.4% of resectional surgery) followed by Trans hiatal
esophagectomy(28.8%). Blood transfusion was required in 7(15.5%) of
patients who underwent resectional surgery. Wound infection occurred in
13.5% of cases while 7.4% of cases had respiratory complications.
Anastomotic leak
Totally 4(8.8%) patients  out of the 45 patients who underwent
resectional surgery had anastomotic leak .  2 patients  out of the 13 patients
who underwent THE had a neck leak  of which one patient  recovered with
conservative management while the other patient died due to coronary
disease. 2 of the 29 patients who underwent  total gastrectomy  had leak
.Leak  in the neck  was associated with less morbidity and mortality
compared to intra abdominal leak.
Among the patients who had leak the mean Hb  was  8.3g%
compared to the overall mean of 9g%.The mean albumin values in patients
who had leak was 3.18g%  compared to the overall mean of 3.27g%.
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Stapler was used in 88% of resectional surgery i.e. at least in the
closure of  duodenal stump. Its use is especially handy in case of
anastomosis done in deep seated locations  like  in the  region around  the
esophageal hiatus of  the diaphragm especially  in siewert type 1 tumors. A
stapler was used for the vital anastomosis in 32(71.1%) patients  out of the
45 patients who underwent resectional surgery.  When applied  optimally ,
staplers help in  standardization of the procedure especially  in an
institution where there are  many operating surgeons.
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CONCLUSION
GE junction cancers represent an emerging health problem.
The incidence of  adenocarcinoma  in this part of the world is on the
rise similar to the west probably due to changing life styles and adaptation
of  western culture. The AJCC 7th edition staging manual for esophageal
carcinoma includes the gastroesophageal junction and harmonizes the
esophageal and gastric cancer staging system .
Surgical resection for cure  remains  the mainstay of treatment at
present. Tailoring  the surgical approach  in accordance  with the
histological type , and siewert type gives the optimal outcome to the
patient.
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APPENDIX
Case record form:
Name
Age
Sex
IP no.-Inpatient number
Diagnosis- Ca.GE jun/GIST
                   Siewert type-1/2/3
                    Leiomyoma-leiomyoma
Histological type-adeno ca./scc
Procedure- THE/TG/FJ
Grade of differentiation-G1/G2/G3
GROSS MORPHOLOGY1-protruding/
2- ulcerative, / 3-infiltrative
Stage-stage of the tumor as per 7th edition
of  AJCC
Preop.Rx- preoperative treatment
CT- chemotherapy
CRT- chemoradio therapy
Pain abd.- Present-1 /Absent-2
Dysphagia- Present-1 , Absent-2
Heart burn- Present-1 , Absent-2
Hemetemesis- Present-1 , Absent-2
Malena- Present-1 , Absent-2
LOW-loss of weight- Present-1 , Absent-2
LOA-loss of appetite- Present-1 , Absent-2
HTN-Present-1 , Absent-2
DM- Present-1 , Absent-2
CAD- Present-1 , Absent-2
COPD-Present-1 , Absent-2
Alcohol- Present-1 , Absent-2
Tobacco chewing- Present-1 , Absent-2
Non veg-Non vegetarian- Yes-1, No-2
Hb%-Haemoglobin in gram%
Alb-Albuminin  in gm/dl
Duration(min)-Duration of surgery in
minutes
Blood loss(ml)- blood loss in millilitres
Blood tr.-blood transfusion- Present-1 ,
Absent-2
Stapled/handsewn-stapled-1,   hand sewn-2
SDH-25/TLC-     SDH25-circular stapler-1
                              TLC-linear cutter        -2
Ro/R1-resection margin   Ro-1
                                          R1-2
Anast.leak-Anastomotic leak  - Present-1 ,
     Absent-2
Stricture- Present-1 , Absent-2
RT removal- Day of  ryle’s tube removal
ICD-intercoastal chest drain inserted-
Yes-1, No-2
DT  removal-  day  of   Drainage   Tube
removal
Oral intake-day of oral intake
Dilatation-Yes-1, No-2
Post.op.ventilatio-Post operative ventilator
support-Yes-1 ,No-2
Extubation da-Day of extubation
Wound in.-wound infection- Yes-1,  No-2
Resp.inf.-Respiratory complications-
Yes-1,  No-2
Post.op.stay-duration of post operative stay
in days
Mortality- Yes-1,  No-2
Chemotherapy-Yes-1, No-2
INFORMED CONSENT FORM – ENGLISH
Title of the study – “AUDIT OF GASTROESOPHAGEAL JUNCTION
TUMORS”
Name of the participant: __________________________________________
Name of the Principal/Co-Investigator: Dr.SREEKANTH.D
Name of the Institution:  MADRAS MEDICAL COLLEGE AND RAJIV
GANDHI GOVERNMENT GENERAL
HOSPITAL
Name and address of the sponsor / agency (ies), if any: Nil
I,_________________(name of participant), have read the information in this
form (or it has been read to me).
I was free to ask any questions and they have been answered. I am over 18 years
of age and, exercising my free power of choice, hereby give my consent to be
included as a participant in “AUDIT OF GASTROESOPHAGEAL JUNCTION
TUMORS”
I have read and understood this consent form and the information provided to
me.
1. I have had the consent document explained to me.
2. I have been explained about the nature of the study.
3. I have been explained about my rights and responsibilities by the
investigator.
4. I have informed the investigator of all the treatments I am taking or
have taken in the past ______ months including any native
(alternative) treatments.
5. I hereby give permission to the investigators to release the information
obtained from me as result of participation in this study to the
sponsors, regulatory authorities, Government agencies, and ethics
committee. I understand that they may inspect my original records.
6. I understand that my identity will be kept confidential if my data are
publicly presented.
7. I have had my questions answered to my satisfaction.
8. I consent voluntarily to participate as a participant in this research
study.
             I am aware, that if I have any questions during this study, I should
contact  the  investigators.  By  signing  this  consent  from,  I  attest  that  the
information given in this document has been clearly explained to me and
understood by me. I will be given a copy of this consent document.
Name and signature / thumb impression of the participant:
(Name) __________________________(Signature)___________________
Date:
Name and signature of the Investigator:
(Name) _________________________(Signature)____________________
Date:


MASTER CHART GUIDE
NA-Not Applicable
Name-Name of the patient
Age
Sex
IP no.-Inpatient number
Diagnosis- Ca.GE jun.-Carcinoma gastroesophageal junction
                  GIST-Gastrointestinal stromal tumor
                   Siewert-1/siewert-2/siewert-3-type of adeno carcinoma
                    Leiomyoma-leiomyoma
Histological type-adeno ca.-Adeno carcinoma
                              Scc-squamous cell carcinoma
Procedure-
 TG- total gastrectomy
 THE- trans haital esophagectomy
 FJ -feeding jejunostomy
 Grade of differentiation
1- Well differentiated
2- Moderately differentiated
3- Poorly differentiated
GROSS MORPHOLOGY
1-protruding
2- ulcerative
3-infiltrative
Stage-stage of the tumor as per 7th edition of  AJCC
Preop.Rx- preoperative treatment
CT- chemotherapy
CRT- chemoradio therapy
Pain abd.-Pain abdomen- Present-1 , Absent-2
Dysphagia- Present-1 , Absent-2
Heart burn- Present-1 , Absent-2
Hemetemesis- Present-1 , Absent-2
Malena- Present-1 , Absent-2
LOW-loss of weight- Present-1 , Absent-2
LOA-loss of appetite- Present-1 , Absent-2
HTN-hypertension- Present-1 , Absent-2
DM-Diabetes mellitus- Present-1 , Absent-2
CAD-coronary artery disease- Present-1 , Absent-2
COPD-chronic obstructive pulmonary disease- Present-1 , Absent-2
Alcohol- Present-1 , Absent-2
Tobacco che-Tobacco chewing- Present-1 , Absent-2
Non veg-Non vegetarian- Yes-1,  No-2
Hb%-Haemoglobin in gram%
Alb-Albumin  in gm/dl
Duration(min)-Duration of surgery in minutes
Blood loss(ml)- blood loss in millilitres
Blood tr.-blood transfusion- Present-1 , Absent-2
Stapled/handsewn-stapled-1,    hand sewn-2
SDH-25/TLC-       SDH25-circular stapler-1
                               TLC-linear cutter        -2
Ro/R1-resection margin   Ro-1
                                          R1-2
Anast.leak-Anastomotic leak  - Present-1 , Absent-2
Stricture- Present-1 , Absent-2
RT removal- Day of  ryle’s tube removal
ICD-intercoastal chest drain inserted-Yes-1, No-2
DT removal- day of  Drainage  Tube removal
Oral intake-day of oral intake
Dilatation-Yes-1, No-2
Post.op.ventilatio-Post operative ventilator support-Yes-1 ,No-2
Extubation da-Day of extubation
Wound in.-wound infection- Yes-1,  No-2
Resp.inf.-Respiratory complications-Yes-1,  No-2
Post.op.stay-duration of post operative stay in days
Mortality- Yes-1,  No-2
Chemotherapy-Yes-1, No-2
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Ambika 25 f 55908 siewert-2 adeno ca. TG 1 1 3 NA 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 9.3 3.2 240 250 2 2 NA 1 2 2 8 2 7 7 2 2 0 2 1 9 2 1
Sivalingam 65 m 61782 Ca.GE jun scc THE 1 1 3 NA 2 1 2 2 2 2 2 2 2 2 2 1 1 1 1 8.2 3.5 300 300 2 2 NA 1 2 1 12 1 5 8 1 2 0 1 2 14 2 1
Baskar 30 m 59651 siewert-2 adeno ca. stag.lap 2 3 4 NA 1 1 1 2 2 1 1 2 2 2 2 2 2 2 1 7 3 60 10 1   NA NA NA NA NA NA 2 NA NA 2 2 0 2 2 5 2 1
Moorthy 50 m 74479 siewert-1 adeno ca. THE 2 3 3 NA 2 1 1 1 1 2 2 2 2 2 2 1 1 2 2 8.8 2.9 300 170 2 2 NA 1 2 2 9 1 8 12 2 1 2 1 1 22 2 1
Thirunavukarasu 64 m 71030 siewert-3 adeno ca. stag.lap 3 3 4 NA 2 1 2 2 2 1 1 2 2 2 1 1 1 1 1 9.2 3 45 10 1   NA NA NA NA NA NA 2 NA NA 2 2 0 2 1 8 2 1
Anusurya 65 f 81683 siewert-3 adeno ca. TG 2 2 3 NA 2 1 1 2 2 2 2 1 2 2 2 2 2 2 1 8.4 3.6 260 190 2 2 NA 1 2 2 8 1 8 9 2 2 0 2 2 11 2 1
Ravichandran 45 m 86607 siewert-3 adeno ca. TG 1 3 3 NA 1 1 2 2 2 1 1 2 2 2 2 1 1 2 1 9.6 3.3 220 100 2 1 1 1 2 2 8 2 7 6 2 2 0 2 2 9 2 1
Sundaramoorthy 38 m 94511 Ca.GE jun scc THE 2 2 3 NA 2 1 2 2 2 1 1 2 2 2 2 2 1 2 1 9.8 3.3 250 150 2 1 1 1 2 2 7 1 4 6 2 2 0 2 2 9 2 1
Vanitha 49 f 65638 siewert-2 adeno ca. TG 1 2 3 NA 2 1 1 1 1 2 1 2 2 2 2 2 2 1 1 8.8 2.9 180 200 2 1 1 2 2 2 7 2 8 7 2 2 0 2 2 13 2 1
Nagalakshmi 48 f 91306 siewert-3 adeno ca. stag.lap 3 3 4 NA 2 1 1 2 2 1 2 2 2 2 2 2 2 2 1 7.8 3.1 70 50 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
Ponnusamy 58 m 95570 siewert-3 adeno ca. TG 2 2 3 NA 2 1 2 2 2 1 1 2 2 2 1 1 1 1 1 9.5 3.2 280 250 2 1 1 1 2 2 7 2 7 6 2 2 0 2 2 10 2 1
Ramesh kumar 54 m 473 siewert-2 adeno ca. staging lap2 3 4 NA 1 2 1 2 2 1 2 2 2 2 1 2 1 2 1 7.2 3 40 5 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
perumal 60 m 107065 siewert-3 adeno ca. TG 2 1 3 NA 2 1 1 2 2 1 1 2 2 2 1 1 1 1 1 8.6 3.1 290 180 2 1 1 1 2 2 7 2 7 7 2 2 0 2 2 10 2 1
Arunachalam 37 m 103739 siewert-1 adeno ca. THE 2 1 3 NA 2 1 1 2 2 2 2 2 2 2 2 2 1 2 1 9.2 3.5 300 200 2 1 2 1 2 2 9 1 7 10 2 2 0 2 2 15 2 1
Shenaz begum 57 f 5225 siewert-2 adeno ca. stag.lap 3 2 4 NA 2 1 2 2 2 1 1 2 2 2 2 2 2 2 1 9.6 3.2 60 10 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
sulochana 56 f 6904 siewert-2 adeno ca. staging lap3 3 4 NA 1 2 1 2 2 1 1 2 2 2 2 2 2 1 1 8.8 3.1 50 15 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
moorthy 50 m 9869 siewert-3 adeno ca.  stag.lap 2 3 4 NA 1 1 2 2 2 1 2 2 2 2 1 1 1 2 1 8.6 3.5 45 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
Komala 65 f 18982 siewert-2 adeno ca. stag.lap 3 3 4 NA 2 1 1 2 2 1 1 2 2 2 2 2 2 2 1 7.5 3.2 55 15 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
kodandaraman 58 m 16373 siewert-2 adeno ca. stag.lap 3 3 4 NA 1 1 1 2 2 1 2 2 2 2 1 2 1 2 1 7.8 3.2 60 10 1   NA NA NA NA NA NA NA NA NA 2 2 0 1 1 7 2 1
Natarajan 77 m 25837 siewert-2 adeno ca. staging lap2 3 4 NA 1 2 1 2 2 1 1 2 2 2 1 1 1 1 1 8.8 3.1 50 5 1   NA NA 1 NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Malliga 26 f 23336 siewert-2 adeno ca. TG 1 2 3 NA 2 1 1 1 1 2 2 2 2 2 2 2 2 2 1 9 3.1 200 180 1 2 NA 1 2 2 10 2 11 10 2 2 0 2 2 14 2 1
Shahul hameed 62 m 69780 siewert-2 adeno ca. staging lap2 2 4 NA 1 2 1 2 2 1 1 1 2 2 2 1 1 1 1 8.9 3.3 45 5 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Ramalakshmaiah 66 m 71572 siewert-3 adeno ca. stag.lap 3 2 4 NA 2 1 2 2 2 1 1 2 2 2 1 1 1 2 1 7.2 3 10 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 1 8 2 1
Mariammal 40 f 70477 siewert-3 adeno ca. TG 3 2 3 NA 1 1 2 2 1 1 2 2 2 2 2 2 2 1 1 9 3.1 160 110 1 1 1 1 2 2 6 2 7 6 2 2 0 2 2 9 2 1
Chandran 64 m 76915 siewert-2 adeno ca. staging lap2 2 4 NA 1 2 1 2 2 1 1 2 2 2 2 1 1 1 1 10.6 3.3 50 5 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Vijaya kumar 57 m 96666 siewert-2 adeno ca. stag.lap 3 1 4 NA 2 1 1 2 2 1 1 2 2 2 1 1 1 2 1 9.1 3.2 60 20 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
Dhanalakshmi 45 f 97664 siewert-3 adeno ca. TG 2 2 3 NA 2 1 2 2 2 2 1 2 2 2 2 2 2 1 1 8.3 3.1 290 180 2 1 1 1 2 2 7 2 7 6 2 2 0 2 2 10 2 1
Karthik 29 m 101210 siewert-2 adeno ca. stag.lap 2 1 4 NA 1 1 1 2 2 1 1 2 2 2 2 2 2 2 1 9.8 3.4 45 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
Immanuel 60 m 102396 siewert-2 adeno ca. TG 1 2 3 NA 2 1 1 1 1 1 2 2 2 2 2 1 1 1 1 7 2.9 190 200 1 1 1 1 2 2 18 2 22 20 2 2 0 2 2 24 2 1
Srinivasan 50 m 100572 siewert-2 adeno ca. stag.lap 2 1 4 NA 2 1 2 2 2 2 1 2 2 2 2 1 1 1 1 9.8 3.5 50 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Rajkumar 61 m 25154 siewert-2 adeno ca. stag.lap 3 1 4 NA 2 1 1 2 2 1 2 1 8 2 1 2 1 1 1 10.4 3.6 60 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Manohari 34 f 39710 siewert-2 adeno ca. staging lap3 3 4 NA 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 11.2 3.5 60 5 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 4 2 1
Selvaraj 52 m 46352 siewert-3 adeno ca. stag.lap 2 2 4 NA 2 1 2 2 2 1 1 2 2 2 1 1 1 1 1 9.3 3.3 90 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Chakravarthy 54 m 43527 siewert-2 adeno ca. proximal gastrec2 1 3 NA 2 1 1 2 2 1 1 2 1 2 2 1 1 1 1 9 3.1 160 110 2 1 1 1 2 2 6 2 7 6 2 2 0 2 2 10 2 1
Masilamani 65 m 47514 siewert-2 adeno ca. stag.lap 3 1 4 NA 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 9.6 3.1 90 20 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Muruganandam 30 m 56597 siewert-1 adeno ca. THE 1 1 3 NA 1 1 1 2 2 2 1 2 2 2 2 2 1 1 1 9.2 3 300 280 2 2 NA 1 1 2 9 2 6 10 2 2 0 1 2 14 2 1
Muniratnam 55 m 99752 siewert-1 adeno ca. THE 1 1 3 NA 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 8.8 3.2 310 250 2 1 2 1 2 2 8 2 6 8 2 2 0 2 2 11 2 1
Munibabu 56 m 72131 Ca.GE jun scc THE 1 2 3 NA 2 1 2 2 2 2 2 2 2 2 2 1 1 1 1 9.5 3.2 290 120 2 1 1 1 2 2 7 2 5 8 2 2 0 2 2 10 2 1
Poongavanam 39 f 61365 siewert-3 adeno ca. TG 2 1 3 NA 11 1 2 2 2 1 1 2 2 2 2 2 2 1 1 9 3.7 160 120 2 1 1 1 2 2 6 2 7 6 2 2 0 2 2 9 2 1
Sundar 57 m 76941 siewert-2 adeno ca. staging lap3 3 4 NA 1 2 1 2 2 1 1 2 2 2 2 1 1 2 1 10.3 3.5 60 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Kuppan 58 m 82666 siewert-3 adeno ca. staging lap3 2 3 NA 1 2 2 2 2 1 2 2 2 2 1 2 2 1 1 8.8 3.1 60 5 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
Ragavan 55 m 81781 siewert-3 adeno ca. staging lap2 3 4 NA 1 2 2 2 2 2 1 1 1 2 2 1 1 2 1 9.4 3.3 70 10 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
Saroja 70 f 95748 siewert-3 adeno ca. staging lap3 1 4 NA 1 2 2 2 2 1 2 2 2 2 2 2 2 2 1 8.1 3 60 5 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 1 9 2 1
Chinnapparaj 70 m 90366 siewert-3 adeno ca. TG+DP+spl2 1 3 NA 2 1 2 2 2 1 1 1 1 1 1 1 1 1 1 9.2 3.3 350 500 2 1 1 1 2 2 8 1 13 11 2 2 0 2 2 16 2 1
Kaliyaperumal 70 m 99538 Ca.GE jun scc THE 1 1 3 NA 2 1 2 2 2 2 2 2 2 2 1 2 1 1 1 9.6 3.2 300 150 2 2 NA 1 2 2 8 1 6 7 2 2 0 2 2 14 2 1
Gnanamoorthy 65 m 101518 siewert-2 adeno ca. FJ 2 2 3 CT 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 8.2 2.8 60 20 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 1 8 2 1
Iqbal 58 m 101643 siewert-2 adeno ca. FJ 3 1 3 CRT 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 9.6 3.5 50 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
selvi 36 f 76516 siewert-3 adeno ca. staging lap3 2 4 NA 1 2 2 2 2 1 1 2 1 2 2 2 2 2 1 9.4 3.3 70 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Jayalakshmi 55 f 56649 siewert-3 adeno ca. FJ 2 1 3 CT 1 2 2 2 2 1 1 2 2 2 2 2 2 2 1 9.2 3.5 65 5 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
shanti 38 f 46273 siewert-2 adeno ca. staging lap3 3 4 NA 1 2 1 2 2 1 1 2 2 2 2 2 2 2 1 10.4 3.2 80 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 6 2 1
marimuthu 38 m 52328 siewert-3 adeno ca. TG 1 1 3 NA 1 1 2 2 2 1 2 2 2 2 2 2 2 2 1 8 3.1 200 180 2 2 NA 1 2 2 10 2 11 10 2 2 0 2 2 14 2 1
karnan 70 m 73234 siewert-3 adeno ca. TG 1 1 3 NA 2 1 2 2 1 1 1 1 2 2 2 2 2 2 1 8 3.1 220 200 2 2 NA 1 2 2 10 2 11 10 2 2 0 2 2 14 2 1
venkatesan 66 m 54976 siewert-2 adeno ca. TG 2 2 3 NA 1 1 1 2 1 2 2 2 2 2 2 1 1 1 1 7 3.1 200 180 1 2 NA 1 2 2 10 2 11 10 2 2 0 2 2 14 2 1
poornima 20 f 93947 leiomyoma  GE junleiomyoma prox. Gastr.NA NA 3 NA 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 12.6 4.2 180 200 2 1 1 2 2 2 7 2 8 7 2 2 0 2 2 10 2 2
arumugam 50 m 63829 GIST GIST(retro+)TG NA NA 3 NA 2 1 2 2 2 1 1 2 2 2 2 1 1 2 1 9.1 3.6 300 200 2 1 1 1 2 2 7 2 7 8 2 2 0 2 2 14 2 1
Madhivanan 43 m 102172 GIST GIST prox.gastrec.NA NA 3 NA 2 1 2 2 2 1 1 2 2 2 2 1 1 2 1 9.8 3.3 280 160 2 1 1 1 2 2 6 2 7 6 2 2 0 2 2 9 2 1
sampath 63 m 72951 GIST GIST TG+metastatectomyNA NA 4 NA 1 1 2 2 2 1 1 2 2 2 2 2 1 2 1 8.3 3.1 410 520 1 1 1 1 2 2 7 2 7 6 2 2 0 1 2 14 2 1
Ruturamary 60 f 12432 ca.GE jun scc THE 1 1 3 NA 2 1 2 2 2 1 1 1 2 2 2 2 2 2 1 10.8 3.3 310 250 2 1 1 1 2 2 7 1 8 7 2 2 0 2 2 11 2 1
chellam.K 50 f 66968 siewert-1 adeno ca. THE 2 1 3 NA 2 1 1 2 2 1 2 1 1 2 2 2 2 2 1 8.8 3.2 300 280 2 1 1 1 2 2 7 1 7 9 2 1 0 2 2 10 2 1
Thillaiammal 57 f 8549 ca. GE jun. scc THE 1 1 3 NA 2 1 2 2 2 2 1 2 2 2 2 2 2 1 1 9.8 3.6 300 180 2 1 2 1 2 2 7 1 3 8 2 2 0 2 2 10 2 1
Nagammal 60 f 18235 ca. GE jun. scc THE 2 2 3 NA 2 1 2 2 2 2 1 2 2 2 2 2 2 2 1 8.4 3.4 270 200 2 1 2 1 2 2 12 1 6 10 2 2 0 2 2 14 2 1
vasantha 50 f 55973 siewert-3 adeno ca. TG 2 1 3 NA 2 1 2 2 2 1 1 1 2 2 2 2 2 2 1 9.5 3.2 180 200 2 1 1 1 2 2 6 2 7 6 2 2 0 2 2 13 2 1
jagadhambal 62 f 81653 siewert-3 adeno ca. TG 1 1 3 NA 1 1 2 2 2 1 1 1 1 2 2 2 2 1 1 7 3 180 200 1 1 1 2 1 2 22 1 22 22 2 2 0 1 1 22 2 1
baskar 57 m 85798 siewert-3 adeno ca. TG 1 2 3 NA 1 1 1 1 1 1 2 2 1 2 2 1 1 2 1 6 2.5 180 200 1 1 1 1 2 2 6 2 7 6 2 2 0 2 2 9 2 1
gnanasekar 41 m 8302/11 siewert-3 adeno ca. stag.lap 3 3 4 NA 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 9.8 3.5 100 60 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
gajendran 50 m 104882 siewert-3 adeno ca. TG 2 1 3 NA 2 1 2 2 2 1 1 2 2 2 2 1 1 2 1 8.8 3.2 280 350 2 1 1 1 2 2 7 2 7 6 2 2 0 2 2 10 2 1
Amsa 40 f 14339 siewert-3 adeno ca. TG 2 1 3 NA 2 1 1 1 1 2 1 2 2 2 2 2 2 2 1 7.9 3.4 160 180 2 1 1 1 2 2 7 2 8 7 2 2 0 2 2 10 2 1
Radhakrishnan 64 m 63373 siewert-3 adeno ca. staging lap3 2 4 NA 1 2 2 2 2 1 1 2 2 2 1 2 1 2 1 11.2 3.5 50 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Santhamary 46 f 61915 siewert-3 adeno ca. stag.lap 2 3 4 NA 2 1 2 2 2 1 1 2 2 2 2 2 2 2 1 10.2 3.3 90 30 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
Mohammed khan 57 m 68018 siewert-3 adeno ca. TG 3 1 3 NA 2 1 1 2 2 1 1 2 2 2 1 2 1 2 1 8.8 3.1 330 300 2 2 NA 1 2 2 14 1 20 22 2 2 0 1 1 28 2 1
Settu 32 m 72148 siewert-3 adeno ca. Inoperable3 3 4 NA 1 2 2 1 2 1 1 1 2 2 2 2 1 1 1 7.6 3 95 50 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
Elumalai 64 m 78652 siewert-3 adeno ca. TG 2 2 3 NA 2 1 1 2 2 1 1 2 2 2 2 1 1 2 1 9.5 3.5 280 230 2 1 1 1 2 2 7 2 7 6 2 2 0 2 2 9 2 1
Gopal 55 m 112589 siewert-3 adeno ca. stag.lap 3 1 4 NA 1 1 2 2 2 1 1 2 2 2 2 1 1 2 1 9.2 3.3 80 10 2   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 5 2 1
Vedapuri 50 m 11967 siewert-3 adeno ca. stag.lap 3 1 4 NA 1 1 2 2 2 1 1 2 2 2 2 1 1 2 1 8.8 3.2 65 15 1   NA NA NA NA NA NA NA NA NA 2 2 0 2 2 7 2 1
shanti 35 f 28284 siewert-3 adeno ca. TG 1 1 3 NA 2 1 1 2 2 1 1 2 2 2 2 2 2 2 1 10.8 3.8 230 150 2 1 1 1 2 2 7 2 8 7 2 2 0 1 2 9 2 1
Maheswari 54 f 60985 siewert-3 adeno ca. TG 1 1 3 NA 2 1 1 2 2 2 1 2 2 2 2 2 2 2 1 11.4 4.2 160 120 2 1 1 1 2 2 6 2 7 6 2 2 0 2 2 9 2 1
Ammaiappan 48 m 63923 siewert-3 adeno ca. TG 1 1 3 NA 2 1 1 2 2 1 1 2 2 2 2 1 1 1 1 8.9 3.5 300 280 2 1 1 1 2 2 7 2 7 8 2 2 0 1 2 11 2 1
Kamatchi 60 f 82679 siewert-3 adeno ca. TG 2 1 3 NA 1 1 2 2 2 2 1 2 2 1 2 2 2 1 1 9.2 3.3 280 200 2 2 NA 1 1 2 NA 2 8 NA 2 2 0 1 1 14 1 2
Durgadevi 34 f 87940 siewert-3 adeno ca. TG 2 1 3 NA 2 1 1 2 2 1 1 2 2 2 2 2 2 2 1 10.2 3.4 290 220 2 1 1 1 2 2 7 2 7 8 2 2 0 1 2 10 2 1
Kuppammal 53 f 16175 ca. GE jun basiloid sq.ccTHE 1 1 3 NA 1 1 2 2 2 1 1 2 2 1 2 2 2 2 1 9.5 3.2 300 350 2 2 NA 1 1 2 NA 1 NA NA 2 2 0 1 1 7 1 2
Sundar 50 m 109306 siewert-2 adeno ca. staging lap3 2 4 NA 1 2 1 2 2 1 1 2 2 2 1 1 1 2 1 7.8 3.6 70 10 1   NA NA 1 NA NA NA 2 NA NA 2 2 0 2 2 5 2 1



